<DOC>
	<DOCNO>NCT01535950</DOCNO>
	<brief_summary>This study ass safety efficacy LFG316 patient age relate macular degeneration .</brief_summary>
	<brief_title>Safety Efficacy Intravitreal LFG316 Wet Age Related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Best correct visual acuity ( ETDRS scale ) 60 letter less study eye . An active choroidal neovascular membrane attributable neovascular AMD least one eye . History treatment ( time ) least 3 dos antiVEGF therapy study eye . History recurrent nonresponse antiVEGF therapy study eye . In study eye , retinal disease AMD ( benign condition vitreous peripheral retina exclusionary ) . Choroidal neovascularization due cause AMD . In study eye , medium opacity , investigator 's opinion , could interfere conduct study . History infectious uveitis endophthalmitis either eye . Any following treatment study eye within 28 day prior dose : ranibizumab , bevacizumab , pegaptanib VEGF inhibitor . Any follow within 90 day prior dose : photodynamic therapy laser photocoagulation study eye ; intravitreal steroid study eye ; intraocular surgery ( include cataract surgery ) study eye</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Age-related macular degeneration</keyword>
	<keyword>intravitreal , neovascular</keyword>
	<keyword>anti-vascular endothelial growth factor</keyword>
	<keyword>wet AMD</keyword>
	<keyword>Age-related</keyword>
	<keyword>Macular degeneration</keyword>
	<keyword>Intravitreal</keyword>
	<keyword>Neovascular</keyword>
</DOC>